Cardiovascular DiseasesPRECEDENCT06909773
The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
A study testing Guideline education and implementation intervention in people with Cardiovascular Diseases, run by AstraZeneca at 85 sites in China.
Trial summary
This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) participants , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF). Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Cardiovascular Diseases
- What is being tested?
- Guideline education and implementation intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,000 participants
- Where
- 85 sitesChina
- Study dates
- 28 Nov 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Give signed written informed consent to participate.
- At least 40 years of age at baseline visit.
- Previous or newly diagnosed by at least one of the 3 types of CVD which are,
- Coronary heart disease ( CHD )
- Atrial fibrillation (AF )
- Chronic heart failure ( CHF )
Show all 19Show fewer
- Participants can undergo spirometry testing and does not have the following serious diseases or disease states：
- Shock within the last 3 months
- Mycardial infarction, stroke or unstable angina within last 1 month
- Currently suffering from severe HF or severe arrhythmia. Severe HF refers to the need for intravenous administration of vasoactive drugs and diuretics; severe arrhythmia refers to arrhythmias that cause hemodynamic instability, such as ventricular fibrillation and ventricular tachycardia
- Severe hemoptysis or active gastrointestinal bleeding within last 1 month
- Patients with seizures requiring medication
- Patients with hypertensive crisis or uncontrolled hypertension [systolic blood pressure > 200 mmHg, diastolic blood pressure > 100 mmHg (1 mmHg = 0.133 kPa)]
- Patients with active respiratory infectious diseases or infectious diseases, such as open pulmonary tuberculosis, influenza, new coronavirus infection, and acute pneumonia
- Patients with aortic or cerebral aneurysms
- Pneumothorax and pneumothorax healing within last 1 month
- Patients with severe hyperthyroidism
- Patients who have recently had eye, ear, cranial or thoracic or abdominal surgery Note: If the patient can cooperate by completing a single, effective forced exhalation (≥6 seconds), then spirometry testing can be performed.
- Subjects have the cognitive ability to conduct questionnaires after e valuated by investigators.
Who cannot join
- Significant diseases or conditions, which, in the opinion of the investigator, may put the participant at risk because of participation in the study or may influence either the results of the study or the participant's ability to participate in the study.
- Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.
- Participant who are not able to provide written informed consent.
- Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.
Trial locations and contacts
85 sites in 1 country. Contact the study team or a site near you to ask about taking part.
AstraZeneca Clinical Study Information Center contact
85 sites in 1 country
China85 sites, 85 recruiting
- Not yet recruiting
Research Site
Anqing, 246004
- Recruiting
Research Site
Beijing, 100029
- Not yet recruiting
Research Site
Beijing, 100029
- Not yet recruiting
Research Site
Beijing, 100037
- Not yet recruiting
Research Site
Beijing, 100050
- Recruiting
Research Site
Beijing, 100191
- Not yet recruiting
Research Site
Changsha, 410005
- Recruiting
Research Site
Changsha, 410300
- Not yet recruiting
Research Site
Chaohu, 238001
- Recruiting
Research Site
Chengdu, 610021
- Recruiting
Research Site
Chengdu, 610041
- Recruiting
Research Site
Chengdu, 610072
- Recruiting
Research Site
Chifeng, 024206
- Recruiting
Research Site
Chongqing, 400010
- Not yet recruiting
Research Site
Dalian, 116001
- Not yet recruiting
Research Site
Dingzhou, 562100
- Not yet recruiting
Research Site
Dongguan, 523009
- Not yet recruiting
Research Site
Foshan, CN-528000
- Recruiting
Research Site
Fuyang, 236400
- Not yet recruiting
Research Site
Fuzhou, 350005
- Recruiting
Research Site
Ganzhou, 341699
- Not yet recruiting
Research Site
Guanghan, 618300
- Not yet recruiting
Research Site
Guangzhou, 510080
- Not yet recruiting
Research Site
Guangzhou, 510100
- Recruiting
Research Site
Guangzhou, 510280
- Not yet recruiting
Research Site
Guangzhou, 510515
- Recruiting
Research Site
Haikou, 570311
- Not yet recruiting
Research Site
Hangzhou, 310016
- Recruiting
Research Site
Hangzhou, 310030
- Recruiting
Research Site
Harbin, 150001
- Recruiting
Research Site
Harbin, 150036
- Not yet recruiting
Research Site
Hefei, 230001
- Recruiting
Research Site
Hefei, 230011
- Recruiting
Research Site
Hubei, 434300
- Recruiting
Research Site
Jinhua, 321099
- Not yet recruiting
Research Site
Jinzhong, 030600
- Recruiting
Research Site
Jiujiang, 332000
- Recruiting
Research Site
Kaiyuan, 661600
- Not yet recruiting
Research Site
Kunming, 650032
- Not yet recruiting
Research Site
Kunming, 650101
- Recruiting
Research Site
Lanzhou, 730000
- Recruiting
Research Site
Leping, 333300
- Not yet recruiting
Research Site
Lianjiang, 524400
- Recruiting
Research Site
Linhai, 317000
- Recruiting
Research Site
Meizhou, 514031
- Recruiting
Research Site
Mianyang, 621000
- Recruiting
Research Site
Nanchang, 330006
- Not yet recruiting
Research Site
Neijiang, 641200
- Recruiting
Research Site
Ningbo, 315600
- Not yet recruiting
Research Site
Ningbo, 315700
- Recruiting
Research Site
Putian, 351106
- Not yet recruiting
Research Site
Quanzhou, 362000
- Recruiting
Research Site
Shanghai, 200072
- Not yet recruiting
Research Site
Shanghai, 200080
- Recruiting
Research Site
Shanghai, 201114
- Not yet recruiting
Research Site
Shanghai, 201199
- Recruiting
Research Site
Shanghai, 201318
- Recruiting
Research Site
Shantou, 515031
- Not yet recruiting
Research Site
Shantou, 515041
- Not yet recruiting
Research Site
Shenyang, 110004
- Not yet recruiting
Research Site
Shenzhen, 518036
- Recruiting
Research Site
Shijiazhuang, 50051
- Recruiting
Research Site
Sichuan, 643200
- Recruiting
Research Site
Suining, 629000
- Recruiting
Research Site
Suzhou, 215300
- Recruiting
Research Site
Tai’an, 271000
- Recruiting
Research Site
Taiyuan, 030001
- Not yet recruiting
Research Site
Taiyuan, 030032
- Not yet recruiting
Research Site
Tianjin, 300050
- Recruiting
Research Site
Tianjin, 300211
- Not yet recruiting
Research Site
Tianjin, 300222
- Not yet recruiting
Research Site
Tianmen, 431700
- Recruiting
Research Site
Wuhan, 430000
- Not yet recruiting
Research Site
Wuhan, 430000
- Not yet recruiting
Research Site
Wuxi, 214122
- Recruiting
Research Site
Xi'an, 710100
- Recruiting
Research Site
Xiamen, 361003
- Recruiting
Research Site
Xiangyang, 441000
- Recruiting
Research Site
Xinzheng, 451100
- Recruiting
Research Site
Xuzhou, 221009
- Recruiting
Research Site
Yangzhou, 225001
- Recruiting
Research Site
Yulin, 537000
- Recruiting
Research Site
Zhangzhou, 363099
- Not yet recruiting
Research Site
Zhengzhou, 450000
- Recruiting
Research Site
Zunyi, 563100
About this study
Official title: The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management -A Multi-center, Prospective, Interventional Study (PRECEDE)
This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) participants , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).
Read the detailed description
The mainly purpose of this study is describe the prevalence of COPD of the participants with 3 types of CVD who are aged 40 years or older, and also observe the effect of cardiopulmonary co management on the short term prognosis of participants with CVD and COPD.
This study will enroll approximately 3,000 participants, with approximately 1,000 participants in each cohort.
- Conditions
- Cardiovascular Diseases
- Being tested
- Guideline education and implementation intervention
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Guideline education and implementation interventionBehavioural
The intervention is implemented at the investigator level and the patient level, consisted of 3 parts：
- Disease education
- Investigator level:All investigators will receive COPD and CVD disease education according to Chinese Guideline pproximately 4 weeks before the first subject is enrolled.
- Patient level:After the subjects are enrolled, the cardiologists and pulmonologist will provide disease education on their respective disease areas,education will be provided every 4 weeks until the end of the study.
- Treatment:Cardiologists and pulmonologists will work together to provide treatment management for subjects with CVD and COPD.
- Follow-up management:the subjects will be followed up every 4 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Guideline education and implementation | Other | Not described Receives: Behavioral: Guideline education and implementation intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
The number and percentage of COPD in participants with CVD,CHD,AF,CHF.
To describe the prevalence of COPD in participants with CVD.
Measured: Baseline
Secondary outcomes (18)
The hospitalization/readmission rate in participants with COPD.
To describe the hospitalization/readmission rate in participants with COPD during the implementation of cardiopulmonary co-management.
Measured: Baseline-week12
The hospitalization/readmission rate in CHD, AF and CHF participants with COPD.
To describe the hospitalization/readmission rate in participants with CVD during the implementation of cardiopulmonary co-management.
Measured: Baseline-week12
Change from baseline in SAQ score in participants with CHD and COPD.
To describe the effects of cardiopulmonary co-management on quality of life, symptoms and activity tolerance in participants with COPD.
Measured: Baseline,week4,week8,week12
Change from baseline in AFEQT score in participants with AF and COPD.
To describe the effects of cardiopulmonary co-management on quality of life, symptoms and activity tolerance in participants with COPD.
Measured: Baseline,week4,week8,week12
Change from baseline in KCCQ score in participants with CHF and COPD.
To describe the effects of cardiopulmonary co-management on quality of life, symptoms and activity tolerance in participants with COPD.
Measured: Baseline,week4,week8,week12
Change from baseline in CAT score in participants with COPD.
To describe the effects of cardiopulmonary co-management on quality of life, symptoms and activity tolerance in participants with COPD.
Measured: Baseline,week4,week8,week12
Change from baseline in SGRQ score in participants with COPD.
To describe the effects of cardiopulmonary co-management on quality of life, symptoms and activity tolerance in participants with COPD.
Measured: Baseline,week4,week8,week12
Change from baseline in 6MWD score in participants with COPD.
To describe the effects of cardiopulmonary co-management on quality of life, symptoms and activity tolerance in participants with COPD.
Measured: Baseline,week4,week8,week12
Change from baseline in pre-dose FEV1 and FVC value
To describe the effects of cardiopulmonary co-management on lung function in participants with COPD.
Measured: Baseline,week12
Change from baseline in FEV1 and FVC value within 4 hours post-dosing.
To describe the effects of cardiopulmonary co-management on lung function in participants with COPD.
Measured: Baseline,week12
The rate of AF recurrence in participants with AF and COPD.
To describe the rate of AF recurrence during the period of cardiopulmonary co-management.
Measured: Baseline-week12
Change from baseline in BNP/NT-proBNP value in the participants with CHF and COPD.
To describe the change of biomarkers in the participants with CVD and COPD during the period of cardiopulmonary co-management.
Measured: Baseline,week12
Change from baseline in blood lipids value(TC, LDL, HDL and TG) in the participants with CHD and COPD.
To describe the change of biomarkers in the participants with CVD and COPD during the period of cardiopulmonary co-management.
Measured: Baseline,week12
Propotion of newly diagnosed COPD participants in subjects with COPD at baseline.
To describe the undiagnosed rate of COPD in participants with CVD.
Measured: Baseline
Propotion of newly diagnosed COPD patients in CHD, AF and CHF participants with COPD at baseline.
To describe the undiagnosed rate of COPD in participants with CVD.
Measured: Baseline
Propotion of participants at high risk of COPD in participants with CVD, CHD, AF and CHF at baseline.
To describe the proportion of participants at high risk of COPD among CVD patients.
Measured: Baseline
Propotion of participants at high risk of COPD diagnosed with COPD in participants with CVD, CHD, AF and CHF at baseline.
To describe the proportion of participants at high risk of COPD among CVD patients.
Measured: Baseline
Distribution of stable COPD medications by drug class (ICS, ICS/LABA, methylxanthines,etc) and others [antibiotics, systemic corticosteroids, traditional Chinese medicine, etc]) in mono or combination at baseline and week 12.
To describe the COPD-related treatment patterns before and after the implementation of cardiopulmonary co-management.
Measured: Baseline,week12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2025
- Study start28 Nov 2025
- Primary completion28 Oct 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06909773
- Sponsor's protocol ID
- D2287L00041
- Acronym
- PRECEDE
- Status last verified
- Aug 2026
- First submitted
- 12 Mar 2025
- Last updated
- 1 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. 'Yes' , indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management -A Multi-center, Prospective, Interventional Study (PRECEDE)
- ClinicalTrials.gov ID
- NCT06909773
- Acronym / sponsor ID
- PRECEDE / D2287L00041
- Conditions
- Cardiovascular Diseases
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 28 Nov 2025 (actual)
- Primary completion
- 28 Oct 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 4 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) participants , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).
Detailed description
The mainly purpose of this study is describe the prevalence of COPD of the participants with 3 types of CVD who are aged 40 years or older, and also observe the effect of cardiopulmonary co management on the short term prognosis of participants with CVD and COPD.
This study will enroll approximately 3,000 participants, with approximately 1,000 participants in each cohort.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Guideline education and implementation | Other | Behavioral: Guideline education and implementation intervention |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (19 listed)
- Give signed written informed consent to participate.
- At least 40 years of age at baseline visit.
- Previous or newly diagnosed by at least one of the 3 types of CVD which are,
- Participants can undergo spirometry testing and does not have the following serious diseases or disease states：
- Subjects have the cognitive ability to conduct questionnaires after e valuated by investigators.
Key exclusion criteria (4 listed)
- Significant diseases or conditions, which, in the opinion of the investigator, may put the participant at risk because of participation in the study or may influence either the results of the study or the participant's ability to participate in the study.
- Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.
- Participant who are not able to provide written informed consent.
- Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Guideline education and implementation interventionThe intervention is implemented at the investigator level and the patient level, consisted of 3 parts： 1. Disease education * Investigator level:All investigators will receive COPD and CVD disease education according to Chinese Guideline pproximately 4 weeks before the first subject is enrolled. * Patient level:After the subjects are enrolled, the cardiologists and pulmonologist will provide disease education on their respective disease areas,education will be provided every 4 weeks until the end of the study. 2. Treatment:Cardiologists and pulmonologists will work together to provide treatment management for subjects with CVD and COPD. 3. Follow-up management:the subjects will be followed up every 4 weeks. | Behavioural | Guideline education and implementation |
Primary outcome
The number and percentage of COPD in participants with CVD,CHD,AF,CHF.
Time frame: Baseline
To describe the prevalence of COPD in participants with CVD.
18 secondary outcomes
The hospitalization/readmission rate in participants with COPD.
Time frame: Baseline-week12
The hospitalization/readmission rate in CHD, AF and CHF participants with COPD.
Time frame: Baseline-week12
Change from baseline in SAQ score in participants with CHD and COPD.
Time frame: Baseline,week4,week8,week12
Change from baseline in AFEQT score in participants with AF and COPD.
Time frame: Baseline,week4,week8,week12
Change from baseline in KCCQ score in participants with CHF and COPD.
Time frame: Baseline,week4,week8,week12
Change from baseline in CAT score in participants with COPD.
Time frame: Baseline,week4,week8,week12
Change from baseline in SGRQ score in participants with COPD.
Time frame: Baseline,week4,week8,week12
Change from baseline in 6MWD score in participants with COPD.
Time frame: Baseline,week4,week8,week12
Change from baseline in pre-dose FEV1 and FVC value
Time frame: Baseline,week12
Change from baseline in FEV1 and FVC value within 4 hours post-dosing.
Time frame: Baseline,week12
The rate of AF recurrence in participants with AF and COPD.
Time frame: Baseline-week12
Change from baseline in BNP/NT-proBNP value in the participants with CHF and COPD.
Time frame: Baseline,week12
Change from baseline in blood lipids value(TC, LDL, HDL and TG) in the participants with CHD and COPD.
Time frame: Baseline,week12
Propotion of newly diagnosed COPD participants in subjects with COPD at baseline.
Time frame: Baseline
Propotion of newly diagnosed COPD patients in CHD, AF and CHF participants with COPD at baseline.
Time frame: Baseline
Propotion of participants at high risk of COPD in participants with CVD, CHD, AF and CHF at baseline.
Time frame: Baseline
Propotion of participants at high risk of COPD diagnosed with COPD in participants with CVD, CHD, AF and CHF at baseline.
Time frame: Baseline
Distribution of stable COPD medications by drug class (ICS, ICS/LABA, methylxanthines,etc) and others [antibiotics, systemic corticosteroids, traditional Chinese medicine, etc]) in mono or combination at baseline and week 12.
Time frame: Baseline,week12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. 'Yes' , indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Related trials for Cardiovascular Diseases
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
AstraZeneca Clinical Study Information Center contact
85 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Guideline education and implementation intervention in people with Cardiovascular Diseases, run by AstraZeneca at 85 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 85 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The number and percentage of COPD in participants with CVD,CHD,AF,CHF. (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.